BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $703 | -19.1% | 10,329 | -3.0% | 0.00% | 0.0% |
| Q2 2023 | $869 | +9.0% | 10,646 | -0.9% | 0.00% | 0.0% |
| Q1 2023 | $797 | +0.3% | 10,738 | +11.9% | 0.00% | 0.0% |
| Q4 2022 | $795 | -99.9% | 9,595 | +295.0% | 0.00% | 0.0% |
| Q3 2022 | $690,000 | +13.1% | 2,429 | +37.9% | 0.00% | 0.0% |
| Q2 2022 | $610,000 | -31.1% | 1,761 | +3.0% | 0.00% | 0.0% |
| Q4 2021 | $885,000 | +3.8% | 1,710 | -2.9% | 0.00% | -25.0% |
| Q3 2021 | $853,000 | +17.0% | 1,761 | +8.7% | 0.00% | +33.3% |
| Q2 2021 | $729,000 | +36.0% | 1,620 | +15.5% | 0.00% | 0.0% |
| Q1 2021 | $536,000 | +94.2% | 1,403 | +61.6% | 0.00% | +200.0% |
| Q4 2020 | $276,000 | +0.4% | 868 | -21.8% | 0.00% | -50.0% |
| Q3 2020 | $275,000 | -6.5% | 1,110 | -0.3% | 0.00% | 0.0% |
| Q2 2020 | $294,000 | +39.3% | 1,113 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $211,000 | -6.6% | 1,113 | +8.3% | 0.00% | +100.0% |
| Q4 2019 | $226,000 | +11.9% | 1,028 | -0.2% | 0.00% | 0.0% |
| Q3 2019 | $202,000 | -6.0% | 1,030 | 0.0% | 0.00% | -50.0% |
| Q2 2019 | $215,000 | +4.9% | 1,030 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $205,000 | -80.9% | 1,030 | -80.4% | 0.00% | -77.8% |
| Q3 2018 | $1,074,000 | +37.7% | 5,263 | -0.2% | 0.01% | +12.5% |
| Q2 2018 | $780,000 | – | 5,273 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |